PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.1122
https://www.valueinhealthjournal.com/article/S1098-3015(19)33500-4/fulltext
Section Title :
Section Order :
10982
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33500-4&doi=10.1016/j.jval.2019.09.1122